BR0015580A - Composições analgésicas contendo buprenorfina - Google Patents

Composições analgésicas contendo buprenorfina

Info

Publication number
BR0015580A
BR0015580A BR0015580-2A BR0015580A BR0015580A BR 0015580 A BR0015580 A BR 0015580A BR 0015580 A BR0015580 A BR 0015580A BR 0015580 A BR0015580 A BR 0015580A
Authority
BR
Brazil
Prior art keywords
buprenorphine
compositions containing
nalmefene
naltrexone
naloxone
Prior art date
Application number
BR0015580-2A
Other languages
English (en)
Inventor
Christopher Bourne Chapleo
Keith Mccormack
Nicolas Calvert Varey
Original Assignee
Reckitt Benckiser Healthcare
Mited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9927359.1A external-priority patent/GB9927359D0/en
Application filed by Reckitt Benckiser Healthcare, Mited filed Critical Reckitt Benckiser Healthcare
Publication of BR0015580A publication Critical patent/BR0015580A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçõES ANALGéSICAS CONTENDO BUPRENORFINA ". Composição analgésica na forma de dosagem unitária parenteral, ou em uma forma de dosagem adequada para distribuição via mucosa, compreendendo uma quantidade de buprenorfina que é inferior à dose clínica necessária para alcançar alívio da dor; e uma quantidade de naloxona de modo que a relação em peso de buprenorfina para naloxona seja na faixa de 12,5:1 a 27,5:1, ou uma quantidade de naltrexona ou nalmefeno de modo que a relação em peso de buprenorfina para naltrexona ou nalmefeno seja na faixa de 12,5:1 a 22,5:1, com o que a ação analgésica da buprenorfina é potencializada pela baixa dose de naloxona, naltrexona ou nalmefeno.
BR0015580-2A 1999-11-19 2000-11-17 Composições analgésicas contendo buprenorfina BR0015580A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9927359.1A GB9927359D0 (en) 1999-11-19 1999-11-19 Improvements in or relating to organic compositions
US17620800P 2000-01-14 2000-01-14
PCT/GB2000/004372 WO2001035942A2 (en) 1999-11-19 2000-11-17 Analgesic compositions containing buprenorphine

Publications (1)

Publication Number Publication Date
BR0015580A true BR0015580A (pt) 2002-07-09

Family

ID=26316086

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015580-2A BR0015580A (pt) 1999-11-19 2000-11-17 Composições analgésicas contendo buprenorfina

Country Status (30)

Country Link
US (4) US6995169B2 (pt)
EP (1) EP1242087B1 (pt)
JP (1) JP4745576B2 (pt)
KR (1) KR100726699B1 (pt)
CN (1) CN100431543C (pt)
AR (1) AR031682A1 (pt)
AT (1) ATE262335T1 (pt)
AU (1) AU777259B2 (pt)
BR (1) BR0015580A (pt)
CA (1) CA2392013C (pt)
CO (1) CO5261517A1 (pt)
CZ (1) CZ303160B6 (pt)
DE (1) DE60009346T2 (pt)
DK (1) DK1242087T3 (pt)
ES (1) ES2214334T3 (pt)
GB (1) GB2356348B (pt)
HU (1) HU229565B1 (pt)
IL (2) IL149580A0 (pt)
MX (1) MXPA02004978A (pt)
NO (1) NO321965B1 (pt)
NZ (1) NZ519023A (pt)
PL (1) PL199727B1 (pt)
PT (1) PT1242087E (pt)
RO (1) RO121174B1 (pt)
RU (1) RU2255737C2 (pt)
SI (1) SI21025B (pt)
SK (1) SK286888B6 (pt)
TR (1) TR200400653T4 (pt)
TW (1) TW550070B (pt)
WO (1) WO2001035942A2 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
US20150031718A1 (en) * 2001-08-06 2015-01-29 Purdue Pharma L.P. Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
WO2004096201A1 (en) 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
EP1765292B1 (en) 2004-06-12 2017-10-04 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
ES2761812T3 (es) * 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
CA2674915C (en) * 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
US8093261B2 (en) 2006-10-24 2012-01-10 The Johns Hopkins University Rapid release mini-tablets provide analgesia in laboratory animals
KR20150082689A (ko) 2006-11-09 2015-07-15 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
US20080199407A1 (en) 2007-02-15 2008-08-21 Slater Kenneth C Drug Detoxification Protocol Using Microdosing
GB2447013A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene
GB2447014A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
GB2447016A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
GB2447015A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
ES2572157T3 (es) * 2007-09-03 2016-05-30 Nanotherapeutics Inc Composiciones en forma de partículas para la administración de fármacos poco solubles
US20090082383A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched buprenorphine
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
CN102724878A (zh) * 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
EP2826467B1 (en) 2010-12-22 2017-08-02 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
PH12014500316B1 (en) 2011-09-19 2018-10-03 Orexo Ab New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
HUE072188T2 (hu) 2012-06-06 2025-10-28 Nalpropion Pharmaceuticals Llc Készítmény magas kardiovaszkuláris kockázatú túlsúlyos és elhízott páciensek kezelésére szolgáló eljárásban történõ alkalmazásra
JP6406713B2 (ja) 2013-01-30 2018-10-17 ファーモレックス セラピューティクス， インコーポレイテッド 低用量薬剤によるうつ病および他の疾患の処置
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
EP3043777B1 (en) * 2013-09-10 2020-04-22 Fresh Cut Development, LLC Sublingual buprenorphine spray
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
EP3134090B1 (en) 2014-04-22 2019-06-05 Otsuka Pharmaceutical Co., Ltd. Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
WO2021158957A1 (en) * 2020-02-05 2021-08-12 Summit Biosciences Inc. Drug products for intranasal administration and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
GB8430109D0 (en) 1984-11-29 1985-01-09 Gkn Technology Ltd Securing components
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
GB2213058B (en) * 1987-12-03 1991-07-17 Reckitt & Colmann Prod Ltd Compositions comprising buprenorphine and naltrexone for treatment of opiate addicts
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US20010006967A1 (en) * 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
RU2077326C1 (ru) * 1992-12-29 1997-04-20 Ярыгин Владимир Никитич Препарат для анальгезии
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
JP2004501094A (ja) * 2000-05-05 2004-01-15 ペイン・セラピューティクス・インコーポレイテッド オピオイドアゴニストの効力を増強するか、またはオピオイドアゴニストの有害な副作用を減弱するための新規な組成物および方法

Also Published As

Publication number Publication date
AR031682A1 (es) 2003-10-01
DE60009346D1 (de) 2004-04-29
EP1242087B1 (en) 2004-03-24
GB2356348A (en) 2001-05-23
WO2001035942A2 (en) 2001-05-25
US20030004178A1 (en) 2003-01-02
US20060058332A1 (en) 2006-03-16
WO2001035942A9 (en) 2002-11-28
JP4745576B2 (ja) 2011-08-10
SI21025A (sl) 2003-04-30
PL199727B1 (pl) 2008-10-31
ATE262335T1 (de) 2004-04-15
ES2214334T3 (es) 2004-09-16
GB2356348B (en) 2002-02-06
IL149580A (en) 2007-05-15
HU229565B1 (hu) 2014-02-28
EP1242087A2 (en) 2002-09-25
CA2392013A1 (en) 2001-05-25
CO5261517A1 (es) 2003-03-31
NZ519023A (en) 2004-11-26
SK8762002A3 (en) 2002-12-03
RU2002116361A (ru) 2004-01-27
SI21025B (sl) 2008-04-30
RU2255737C2 (ru) 2005-07-10
HUP0203588A2 (hu) 2003-03-28
US20060058333A1 (en) 2006-03-16
HUP0203588A3 (en) 2005-01-28
SK286888B6 (sk) 2009-07-06
DK1242087T3 (da) 2004-07-19
NO20022330D0 (no) 2002-05-15
AU1529701A (en) 2001-05-30
CZ303160B6 (cs) 2012-05-09
NO20022330L (no) 2002-07-04
TR200400653T4 (tr) 2004-04-21
RO121174B1 (ro) 2007-01-30
NO321965B1 (no) 2006-07-31
KR100726699B1 (ko) 2007-06-13
JP2003514013A (ja) 2003-04-15
PT1242087E (pt) 2004-06-30
CN100431543C (zh) 2008-11-12
US20060069113A1 (en) 2006-03-30
CA2392013C (en) 2009-08-11
IL149580A0 (en) 2002-11-10
CN1413110A (zh) 2003-04-23
HK1055389A1 (zh) 2004-01-09
WO2001035942A3 (en) 2002-06-13
AU777259B2 (en) 2004-10-07
GB0028088D0 (en) 2001-01-03
US6995169B2 (en) 2006-02-07
TW550070B (en) 2003-09-01
KR20020058022A (ko) 2002-07-12
DE60009346T2 (de) 2005-02-10
MXPA02004978A (es) 2003-01-28
PL355330A1 (en) 2004-04-19
US7402591B2 (en) 2008-07-22

Similar Documents

Publication Publication Date Title
CA2392013A1 (en) Analgesic compositions containing buprenorphine in combination with naloxone, naltrexone or nalmefene
BRPI0414876A (pt) compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
BR0212019A (pt) Formas de dosagem, métodos para o tratamento da dor, métodos de preparação de uma forma de dosagem e métodos para impedir o abuso de uma forma de dosagem
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
BR9813827A (pt) Analgésico opióide aplicável em mamìferos e método para impedir o uso oral abusivo de uma formulação opióide oral
BR9915964A (pt) Composição farmacêutica, forma de dosagem oral da mesma, processo de preparar uma composição farmacêutica, método de tratar uma condição ou um distúrbio onde o tratamento com um bloqueador do receptor de aldosterona é indicado e uso de eplerenona micronizada e de um material veìculo celulósico
IL115871A (en) Pharmaceutical composition containing a melt-extruded blend of components and a method for the preparation thereof
PA8479201A1 (es) Derivados del acido hidroxi-pipecolato hidroxamico
BR9814018A (pt) Derivados de tienopirimidina e tienopiridina úteis como agentes anticâncer
BR0111908A (pt) Composto, composição farmacêutica, uso do composto, e, método para o tratamento e/ou prevenção de distúrbios ou doenças
BR9812162A (pt) Composições analgésicas compreendendo compostos antiepiléticos e métodos para o uso das mesmas
EP0871488A4 (en) ANAL-SAFE SYNERGY THROUGH SIMULTANEOUS ADMINISTRATION OF SUBANAL-SIDED CANES FROM A MU OPIOID ANAGONIST AND A KAPPA - 2 OPIOID ANAGONIST
BR0316948A (pt) Composto, formulação farmacêutica, e, uso de um composto
WO2009152189A8 (en) Low dose topiramate/phentermine compostion and methods of use thereof
MY132705A (en) Novel compounds with analgesic effect
YU49026B (sh) UPOTREBA 17 Гџ -(N-TERC-BUTILKARBAMOIL)-4-AZA-5-ALFA-ANDROST-1-3-ON ZA PROIZVODNJU LEKA ZA TRETIRANJE ANDROGENE ALOPECIJE
BR0215193A (pt) Formulações de azitromicina diretamente compressìveis
WO2002058620A3 (es) Composiciones farmaceuticas que contienen un inhibidor de cox-ii y un relajante muscular
PL405074A1 (pl) Zastosowanie alpha-cyklodrkstryny do wytwarzania leku do obnizenia poziomów trójglicerydów
BR0111207A (pt) Combinações de um antagonista receptor de endotelina e um composto antiepiléptico tendo propriedades de alìvio da dor ou analgésicos
BRPI0413693A (pt) composição farmacêutica para a prevenção e tratamento da viciação em um mamìfero
AU1206292A (en) Therapeutic agents for the treatment of multidrug resistance to cancers
HK80492A (en) Pharmaceutical compositions with analgesic properties and the preparation and use thereof
KR900007424A (ko) 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물
TR200002078T2 (tr) Sentetik polisakkaridler, hazırlanmaları için proses ve bunları içeren farmasötik kompozisyonlar.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.